Pharmacokinetics of intravenous omeprazole in children
- PMID: 7859807
- DOI: 10.1007/BF00194970
Pharmacokinetics of intravenous omeprazole in children
Abstract
This study was undertaken to define the pharmacokinetics of omeprazole in children and included 13 patients, heterogeneous in terms of age (0.3 to 19 years), underlying disease and biological constants, indication of omeprazole administration and associated therapy. The dose administered ranged from 36.9 to 139 mg.1.73 m-2. The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 l.kg-1.h-1; volume of distribution, 0.45 l.kg-1; elimination half life 0.86 h; but were highly variable between individuals. Dosage, differences in hepatic and renal function and associated therapy may contribute to inter-individual variability. Within the range of doses administered, the pharmacokinetic parameters were similar to those reported in adults. The drug has been well tolerated in all children.
Similar articles
-
Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.Am J Gastroenterol. 2000 Nov;95(11):3101-6. doi: 10.1111/j.1572-0241.2000.03256.x. Am J Gastroenterol. 2000. PMID: 11095324 Clinical Trial.
-
Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.Clin Pharmacol Ther. 2002 May;71(5):359-67. doi: 10.1067/mcp.2002.122472. Clin Pharmacol Ther. 2002. PMID: 12011821
-
0.5 mg/kg versus 1 mg/kg of intravenous omeprazole for the prophylaxis of gastrointestinal bleeding in critically ill children: a randomized study.J Pediatr. 2013 Apr;162(4):776-782.e1. doi: 10.1016/j.jpeds.2012.10.010. Epub 2012 Nov 10. J Pediatr. 2013. PMID: 23149178 Clinical Trial.
-
Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.Eur J Clin Pharmacol. 2010 Apr;66(4):323-30. doi: 10.1007/s00228-009-0774-9. Epub 2009 Dec 30. Eur J Clin Pharmacol. 2010. PMID: 20041322 Review.
-
The pharmacology of esomeprazole and its role in gastric acid related diseases.Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1113-24. doi: 10.1517/17425250903124363. Expert Opin Drug Metab Toxicol. 2009. PMID: 19606942 Review.
Cited by
-
Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.Clin Pharmacokinet. 2010 Jul;49(7):479-92. doi: 10.2165/11531830-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20528008
-
Pharmacokinetic considerations in the eradication of Helicobacter pylori.Clin Pharmacokinet. 2000 Mar;38(3):243-70. doi: 10.2165/00003088-200038030-00004. Clin Pharmacokinet. 2000. PMID: 10749519 Review.
-
Clinical Pharmacology Studies in Critically Ill Children.Pharm Res. 2017 Jan;34(1):7-24. doi: 10.1007/s11095-016-2033-y. Epub 2016 Sep 1. Pharm Res. 2017. PMID: 27585904 Free PMC article. Review.
-
Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.Paediatr Drugs. 2002;4(10):673-85. doi: 10.2165/00128072-200204100-00004. Paediatr Drugs. 2002. PMID: 12269842
-
Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.Drugs. 1998 Sep;56(3):447-86. doi: 10.2165/00003495-199856030-00012. Drugs. 1998. PMID: 9777317 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources